Diagnostics – resistance, viral load testing
Patient Information Security
HIV Activism at 30
HIV Drug Resistance
Estimating loss to follow up among patients accessing HIV care in England, Wales and Northern Ireland
Less frequent tests, impact on HIV care?
Patient reporting of medicines-related problems
Company meeting: none
Meeting report (to follow)
…………………………………………………
TB and HIV
TB and HIV – treatment and screening
TB-HIV Strengthening community response
Company pre-meeting on TMC207
UKCAB London drug survey feedback
Company meeting: Janssen
CAB41 meeting report
…………………………………………………
Gender and HIV Research
Gender and HIV research: history and overview
Outcomes in HIV positive women
The XX Factor – Women and HIV
London HIV drug prescribing update and survey
Company meeting: BMS
CAB 40 Meeting report
…………………………………………………
London HIV drug prescribing and Hepatitis C
Introduction to London HIV drug
NAT response to London HIV drug prescribing
Moderated discussion on London HIV drug BHIVA standards of care document – community input
HCV – where next?
Q & A
Company meeting: none
CAB39 meeting report
…………………………………………………
HIV and the brain
HIV and brain function
HIV, antiretroviral therapy and the brain
Changes to HIV drug prescribing in London and what implications this could have for the rest of the UK
Company meeting: Abbott
CAB38 meeting report
…………………………………………………
Treatement as prevention
iPrEX Trial Design, statistical aspect of the results relating to the adherence data
Science behind PrEP/Pharmacology training; complexity of how drugs are absorbed and measured indifferent body compartments, and particularly for PrEP
PIVOT Tril: Possible analyses of collected data
Company meeting: Gilead
CAB37 meeting report
…………………………………………………
Making the most of your GP
General Practice and HIV/AIDS
Accessing GP Care: the patient’s perspective
Outcomes in HIV
IAS Vienna 2010
Company meeting: none
CAB36 meeting report
…………………………………………………
Early Diagnosis and Primary Infection
Early Diagnosis and Primary Infection
CASCADE – Seroconverters Database
Vienna preview – a guide on what to look out for
BHIVA Feedback
Company meeting: Merck
CAB35 meeting report
…………………………………………………
Community Training Day
What are observational studies
The UK Collaborative HIV Cohort Study
The UK HIV Drug Resistance Database
National Study of HIV in Pregnancy and Childhood
HPA Surveillance databases
New IT methods to protect data
How do we analyse observational databases
Company meeting: none
CAB34 meeting report
…………………………………………………
African Treatment Issues and Late Diagnosis
Issues for African sub-groups
Pre-Meeting for Gilead
CROI Feedback
Company meeting: Gilead
CAB33 meeting report
…………………………………………………
Advocacy training day
Confidence building workshop
Skill-building session
NHS structures in the UK
Getting other advocates involved
What next – active involvement
Company meeting: none
CAB32 meeting report
…………………………………………………
Ageing and HIV
UKCHIC Proposed Ageing Study
Ageing with HIV: Project Overview Will we ever get to be old and wise?
BHIVA Conference overview
Pre-meeting for Abbott
HIV and Ageing interactive session
Company meeting: Abbott
CAB31 meeting report
…………………………………………………
BHIVA Routine Monitoring Guidelines
HIV Treatment Advocacy Overview
Definitions of Advocacy
Denver Principles
History of Advocacy Film highlights
Advocacy Training in Practice
Pre-Meeting for Bristol-Myers Squibb
IAS Conference Feedback
Company meeting: BMS
CAB30 meeting report
…………………………………………………
Resistance Revisited
Introducing the HIV Vaccine Advisory,Board-Ken Legg, MRC and St Marys Hospital
Resistance Explored,Professor Deenan Pillay
Company meeting: GSK abacavir, pipeline drugs and merger
CAB29 meeting report
…………………………………………………
Late Presenters
Training and presentations: Immunology
Company meeting:Tibotec
Etravirine overview including comment on drug interaction,
Darunavir European license extended to all treatment-experienced
Rilpivirine (TMC-278) Next generation first-line NNRTI and pipeline HIV plus HCV and TB
CAB28 meeting report
…………………………………………………
Transition from Paediatric Care to Adult Services.
Training and presentations:
Mexico Feedback
BHIVA Education Scientific Committee Feedback
BHIVHA/CHIVHA Feedback
Update on the HCQ and PIVOT trials.
Transitional Care from Paediatric to Adult Services: A Clinical Care Perspective.
Young People and HIV: A Social Support Perspective
Company meeting: BMS
CAB27 meeting report
…………………………………………………
TB and HIV
Reporting adverse drug reactions
Training and presentations:
TB and HIV
Yellow Card scheme for reporting adverse drug reactions
Feedback from UNGASS
New York and Resistance Workshop
Sitges
Company meeting: Theratechnologies
…………………………………………………
Reading study results
D:A:D study
BHIVA treatment guidelines
Company meeting: GSK
Training and presentations:
Interpreting risk and confidence in study results
D:A:D study: abacavir, ddI and risk of heart attack
Conference feedback from CROI 2008
Company meeting: GlaxoSmithKline – abacavir and data on risk of heart attack, drugs in development.
Community consultation: BHIVA draft treatment guidelines
…………………………………………………
BHIVA 2007 clinical audit
Training and presentations:
BHIVA 2007 clinical audit: treatment of naïve patients
Campaigning for microbicides
Promoting PEPSE: role of the HIV treatment advocate
PrEP (pre-exposure prophylaxis).
Company meeting: Pfizer – the drug development process.
…………………………………………………
Access to treatment for migrants and people facing deportation
Training and presentations:
Access to treatment for migrants and people facing deportation: the clinician’s perspective
HIV in removal centres
Feedback from European AIDS Clinical Society Conference 2007, Madrid
Company meeting: Roche – nelfinavir recall, GEMINI study, Biojector.
…………………………………………………
HIV testing and monitoring
Training and presentations:
Rapid testing in practice – testing: the standard of care and some other useful tests
Viral tropism
Monitoring HIV infection and treatment in the 2nd decade of HAART
Feedback from AIDS Impact Conference
Yellow Card scheme.
Company meeting: none
…………………………………………………
African treatment issues – Merck
Training and presentations:
UK HIV drug resistance database
Genetics and higher NNRTI levels in Africans
African treatment issues: response to treatment, side effects
Treatment access and other issues
Feedback from CROI 2007: new pipeline drugs.
Company meeting: Merck – raltegravir and integrase inhibitors.
…………………………………………………
London HIV commissioning – renal toxicity
Training and presentations:
London HIV commissioning
Renal toxicity studies
Company meeting: Gilead – Atripla registration, renal studies and tenofovir, drugs in development.
…………………………………………………
BHIVA standards project
Training and presentations:
BHIVA standards project
Feedback from International Congress on HIV and Drug Therapy 2006, Glasgow.
Company meeting: none.
…………………………………………………
HIV related dementia
Training and presentations:
HIV related brain impairment – feedback from World Haemophilia Congress 2006, Vancouver, AIDS 2006, Toronto
Meetings on HIV transmission and criminalisation.
Company meeting: none
…………………………………………………
Cancer and HIV
Training and presentations:
Cancer and HIV
Feedback from BHIVA
EATG and NAM seminar on new drugs
Company meeting: Gilead – ‘One a day’ pill development, new integrase inhibitors.
…………………………………………………
HIV related brain impairment
Training and presentations:
HIV related brain impairment
National Treatment Support Project
SMART study
Company meeting: Tibotec – TMC-114 and TMC-125.
…………………………………………………
Treatment access in eastern Europe
Training and presentations:
Treatment access in eastern Europe
Hepatitis C coinfection
Feedback from BHIVA conference
European AIDS Clinical Society Conference 2005
Dublin and International Workshop on Adverse Drug Reactions and Lipodystrophy 2005, Dublin
Global Fund
Company meeting: Pfizer – CCR5 inhibitors
…………………………………………………
MRC Clinical Trials Unit – Roche
Training and presentations:
Medical Research Council Clinical Trials Unit
Feedback from 3rd IAS conference, Rio
Company meeting: Roche – T20, Biojector and plans for its availability in the UK.
…………………………………………………
Introduction to immunology – entry inhibitors.
Training and presentations:
Introduction to immunology
Entry inhibitors
Feeback from BHIVA
CROI 2005 and South African PWA conference
Company meeting: none
…………………………………………………
Children and HIV – UK treatment guidelines
Training and presentations:
Approaches to paediatric HIV care
UK treatment guidelines.
Company meeting: none
…………………………………………………
Community participation in preventive HIV vaccine trials
Training and presentations:
Approaches to community participation in preventive HIV vaccine trials
Feedback from International Congress on HIV and Drug Therapy 2004, Glasgow.
Company meeting: none
…………………………………………………
Introduction to statistics 3, AIDS 2004 conference
Training and presentations:
Introduction to statistics session 5-6 – feedback from AIDS 2004
Bangkok: mother-to-child transmission, harm reduction and IDUs
3TC monotherapy
Kaletra monotherapy
Pharmacology and drug interactions, treatment access.
Company meeting: none
…………………………………………………
Vaccines and microbicides – Tibotec
Training and presentations:
Introduction to basic vaccine technology
Topical microbicides
Internationl AIDS Vaccine Initiative (IAVI)
Community involvement in vaccine and microbicide research
Thorny issues in HIV vaccine research
Feedback from BHIVA conference
Company meeting: Tibotec – TMC-120
…………………………………………………
Introduction to statistics 2 – BMS
>Training and presentations:
Introduction to statistics Sessions 3-4
Hepatitis C coinfection: APRICOT study
Feedback from CROI 2004: mother to child transmission, women, hepatitis C coinfection.
Company meeting: BMS – Atazanavir: update, access and pricing in UK.
…………………………………………………
Introduction to statistics 1 – Gilead
>Training and presentations:
Introduction to statistics sessions 1-2
Company meeting: Gilead – Tenofovir drug interactions.
…………………………………………………
IAS conference feedback
Training and presentations:
New data from 2nd IAS conference, Paris
Trizivir, emtricitabine, nuke-sparing combinations, atazanavir and boosted PI regimens T20,
New formulations of nelfinavir and saquinavir
SIMBA study (reducing mother-to-baby transmission and breast-feeding)
Feedback from lipodystrophy and resistance workshops
Company meeting: GlaxoSmithKline – ACTG 5095 study, abacavir and tenofovirinteraction, fosamprenavir, neuropathy, viral fitness.
…………………………………………………
Access to treatment, TB and HIV
Training and presentations:
Access to treatment in the UK: working with HIV-positive refugees and asylum seekers
TB and HIV
Company meeting: Roche – T20
…………………………………………………
Women and HIV – HIV, coinfections and multiple conditions
Training and presentations:
Women and HIV: why gender is a real issue
Hepatitis C coinfection
Living with multiple conditions
48 weeks of interferon and ribavirin: was it worth it?
Company meeting: Roche – Hepatitis C products: trial results, side effects, pricing and access, future developments.
…………………………………………………
HIV, pregnancy and maternal heath – Boehringer Ingelheim
Training and presentations:
Of mothers, orphans and the HIV pandemic
Principles of care of the HIV-1 infected pregnant mother
Fertility treatment and spermashing
Company meeting: Boehringer Ingelheim
- Tipranavir: trials, resistance and clinical data
- nevirapine use in pregnancy,
- drugs in development: hepatitis C protease inhibitor
…………………………………………………
Resistance, salvage therapy
Training and presentations:
Basic mechanisms of resistance: how to avoid resistance, when to change treatment, how to interpret different resistance tests
Approaches to salvage therapy: avoiding initial failure
Mega-HAART including OPTIMA study, treatment interruptions, use of new drugs.
Company meeting: BMS
- Atazanavir: overview, resistance, safety, side effects, lipids and expanded access programme
- ddI interaction with tenofovir,
- d4T XR, BMS-561390 (DPC-083).
…………………………………………………
UK-CABs – clinical trials
Training and presentations:
Clinical trials: structure, timelines, design, basic statistics and study power
Informed consent and patient involvement in trials
Role of advocates – UK, European and US CABs (Community Advisory Boards)
Company meeting: Gilead
- tenofovir
- adefovir for hepatitis B
- cidofovir